chr3-10142149-T-G
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PS1_ModeratePM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000551.4(VHL):c.302T>G(p.Leu101Arg) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L101G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000551.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.302T>G | p.Leu101Arg | missense_variant | Exon 1 of 3 | ENST00000256474.3 | NP_000542.1 | |
VHL | NM_001354723.2 | c.302T>G | p.Leu101Arg | missense_variant | Exon 1 of 3 | NP_001341652.1 | ||
VHL | NM_198156.3 | c.302T>G | p.Leu101Arg | missense_variant | Exon 1 of 2 | NP_937799.1 | ||
VHL | NR_176335.1 | n.372T>G | non_coding_transcript_exon_variant | Exon 1 of 4 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome Pathogenic:1
This variant is considered likely pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 24112165, 25078357, 12624160]. This variant is expected to disrupt protein structure [Myriad internal data]. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.L101R variant (also known as c.302T>G and 515T>G), located in coding exon 1 of the VHL gene, results from a T to G substitution at nucleotide position 302. The leucine at codon 101 is replaced by arginine, an amino acid with dissimilar properties. This variant has been identified in multiple VHL probands with either VHL type 1 or VHL, type unspecified (Zbar, B et al. Hum Mutat. 1996;8(4):348-57; Rocha, JC et al. J Med Genet. 2003 Mar;40(3):e31; Kim, HJ et al. Laryngoscope. 2013 Feb;123(2):477-83). In one Chinese VHL type 1 family, 2/2 affected individuals and one unaffected 8-year-old were found to carry this alteration while 6 unaffected individuals tested negative (Gao, Y et al. Chin Med J (Engl). 2013;126(19):3690-3). By estimating the change in free energy between the wild-type and mutant VHL protein using an in silico model, Gao et al. predicted that this missense alteration may lead to a reduced level of protein stability. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 5126 samples (10252 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.02% (greater than 4,300 alleles tested) in our clinical cohort. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be possibly damaging and deleterious by PolyPhen and SIFT in silico analyses, respectively. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.